[4] This potential influence is thought to initiate a cascade of cellular signaling mechanisms
[...] Novo Nordisk v Pro Health Investments, Complaint Return to the list of compounded GLP-1 lawsuits United States District Court Western District of Tennessee Novo Nordisk v Pro Health Investments, LLC Complaint June 20, 2023 Read the document
Individual timelines vary based on starting dose, body composition, and metabolic factorssome people report improvement within days, while others notice persistent tiredness for several weeks
B5 B6
The market has seen strong traction from newer therapies such as: Eli Lillys Mounjaro (tirzepatide), launched in the UK in February 2024 and made available via the NHS in March 2025 Novo Nordisks Wegovy (semaglutide), introduced in the UK in September 2023 through specialist NHS weight-management services While these newer molecules dominate headlines, liraglutide remains a widely prescribed and proven therapy, and Biocons entry offers a more affordable alternativea key differentiator in public healthcare systems
A real-world study of over 20,000 patients found that 17.7% of semaglutide users regained all the weight they had lost, or even exceeded their initial weight, within one year of stopping
